Comprehensive assessment of hemostasis in a patient with an inhibitory form of hemophilia A under emicizumab treatment: 616-005.2:616.151.514-08

Abstract

Summary. The field of novel therapeutics for hemophilia has seen significant advances in recent years. In addition to clotting factor replacement the non-factor therapy is now available — the use of agents that do not contain plasma or recombinant coagula- tion factor, but mimic its action or affect other parts of the hemostasis system. Currently, the clinical practice for the hemophilia treatment replenished by emicizumab — bispecific antibody mimicking activated factor VIII but not by changing its activity, and therefore some of laboratory questions remain unresolved.

References:

1. KuznikB.I., SturovV.G., Levshin N.Yu. et al. Hemorrhagic and thrombotic diseases and syndromes in children and adolescents. Pathogenesis, clinic, diagnosis, therapy and prevention. Novosi­ birsk: Nauka, 2018. 524 рр. (In Russ.).

1. Andreeva T.A., Zorenko V. Yu., Davydkin I.L. et al. Efficiency and safety of Octofactor in the treatment of patients with severe and moderate hemophilia A: results of part 2 of phase II–III clinical trial. Voprosy gematologii/onkologii i immunopatologii v pediatrii. 2013;12(4):31–7. (In Russ.).

1. Zozulya N.I., Kumskova M.A., Polyanskaya T. Yu., Svirin P.V. Clin- ical guidelines for the diagnosis and treatment of hemophilia. Nacional’noe gematologicheskoe obshchestvo, 2018. 34 рp. (In Russ.). Available at: https://npngo.ru/uploads/media_document/284/6a bc18ec-97fe-468f-9235–8c0084874289.pdf. 

2. Florinskiy D.B., Zharkov P.A. Modern approaches in hemophilia therapy. Voprosy gematologii/onkologii i immunopatologii v pedi­ atrii. 2020;19(3):131–8. (In Russ.). DOI: 10.24287/1726–1708–2020– 19–3–131–138.
3. Ataeva A.N., Mirakhmedova S.A., Yarotskaya V. Yu. Present situa- tion in hemophilia therapy: current standards and future expec- tations. Tromboz, gemostaz i reologiya. 2020;(3):11–9. (In Russ.). DOI 10.25555/THR.2020.3.0924.

1. Zozulya N.I., Konyashina N.I., Andreeva T.A. et al. Expert Coun- cil Resolution on laboratory diagnostics in hemophilia A patients receiving Emicizumab. Rossijskij zhurnal detskoj gematologii i onko­ logii. 2020;7(S4):23–4. (In Russ.).

1. Tripodi A., Chantarangkul V., Novembrino C., Peyvandi F. et al. Advances in the treatment of hemophila: implications for laboratory testing. Clin Chem. 2019;65(2):254–62. DOI: 10.1373/ clinchem.2017.284356.
2. Muller J., Pekrul I., Potzsch B. et al. Laboratory monitoring in emicizumab-treated persons with hemophilia A. Thromb Haemost. 2019;119(9):1384–93. DOI: 10.1055/s-0039–1692427.